YD Bio and EG BioMed Partner with JoiiUp to Launch AI-Driven Cancer Risk Assessment for Corporate Wellness Programs
YD Bio, its Taiwan affiliate EG BioMed, and digital health provider JoiiUp launched an AI Cancer Risk Assessment integrated into JoiiUp's JoiiSports app for corporate wellness programs. The questionnaire-based tool, validated on over 1,200 clinical records with three Taipei Medical University affiliated hospitals, analyzes risk across ten cancer types and reaches JoiiUp's network of over 400 corporate clients.
Key figures
- Corporate clients reached
- 400
- Clinical records validated
- 1200
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.